Shanton, Present

Shanton to Present Topline Data from Phase 2b Study with SAP-001 in Refractory Gout Patients at EULAR 2025 Congress

Veröffentlicht: 07.08.2025 um 18:08 Uhr, prnewswire.co.uk

Shanton Pharma New Jersey Singapore

en | boerse | 67934753 |